Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS Analysis

Expert Helen Ajufo, MD, reviews data from the PERSIST-2 overall survival analysis and its implications for the management of patients with myelofibrosis.

Funding supported by CTI Bio. Content independently developed by OncLive®